U.S. Vaccine Panel to Vote on Delaying Hepatitis B Vaccine Birth Dose
The CDC's Advisory Committee on Immunization Practices is set to vote on a proposal to delay the initial hepatitis B vaccine dose for newborns from birth to two months of age.
The Advisory Committee on Immunization Practices (ACIP), which advises the U.S. Centers for Disease Control and Prevention (CDC), is scheduled to vote on a proposal to delay the administration of the hepatitis B vaccine's initial dose from birth to two months of age for most American infants. This potential shift in vaccination protocol could impact how newborns receive early immunizations against hepatitis B.
The current CDC guidelines recommend administering the first dose within 24 hours of birth, followed by two more doses at 1-2 months and 6-18 months. This schedule has been in place since 1991 and is credited with reducing hepatitis B infections in children by over 95%.
Health Secretary Robert F. Kennedy Jr., known for his vaccine-skeptical views, has restructured the ACIP, appointing members who have previously expressed anti-vaccine sentiments. Critics express concern that delaying the hepatitis B birth dose could lead to an increase in chronic infections among children. Hepatitis B can be transmitted from mother to child during childbirth and may result in liver disease and early death. There is no cure for the disease.
The American Academy of Pediatrics continues to recommend the universal birth dose of the hepatitis B vaccine, emphasizing its role in saving lives. A recent review of over 400 studies spanning four decades found no evidence that delaying the universal hepatitis B vaccine birth dose improves safety or effectiveness. The review also found that the birth dose does not cause any short- or long-term serious adverse events or deaths.
Decisions by the ACIP are not legally binding, as it is up to states to mandate immunizations. However, the committee's recommendations significantly influence whether private insurance plans and government assistance programs cover vaccines at no cost for eligible children.
The upcoming two-day meeting in Atlanta follows a previous session in September, where the panel postponed a vote on the hepatitis B vaccine to allow for a more robust discussion. The outcome of this vote may alter standard pediatric vaccination schedules in the United States.